- Report
- March 2025
- 250 Pages
Global
From €4134EUR$4,490USD£3,477GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2302EUR$2,500USD£1,936GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1381EUR$1,500USD£1,162GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1151EUR$1,250USD£968GBP
- Report
- November 2022
- 154 Pages
Global
From €4603EUR$5,000USD£3,872GBP
- Report
- July 2020
- 1200 Pages
Japan
From €2762EUR$3,000USD£2,323GBP
- Report
- June 2020
- 753 Pages
Global
From €3038EUR$3,300USD£2,556GBP
- Report
- September 2021
- 40 Pages
China
From €2394EUR$2,600USD£2,013GBP
- Report
- January 2022
- 224 Pages
Global
From €6398EUR$6,950USD£5,382GBP
Alectinib is an oncology drug used to treat certain types of non-small cell lung cancer (NSCLC). It is a type of tyrosine kinase inhibitor (TKI) that works by blocking the activity of a protein called anaplastic lymphoma kinase (ALK). This protein is found in some types of NSCLC and is responsible for the growth and spread of cancer cells. Alectinib is used to treat patients with ALK-positive NSCLC who have not been treated with chemotherapy or have progressed after treatment with crizotinib. It is also used to treat patients with ALK-positive NSCLC who have progressed after treatment with chemotherapy.
Alectinib is available in tablet form and is taken orally. It is usually taken twice a day with or without food. Common side effects include fatigue, nausea, constipation, and diarrhea.
Alectinib is marketed by several companies, including Genentech, Chugai Pharmaceuticals, and Hoffmann-La Roche. It is also available in generic form from several generic drug manufacturers. Show Less Read more
